Transplant kidney biopsy for proteinuria with stable creatinine: Findings and outcomes.


Journal

Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240

Informations de publication

Date de publication:
10 2021
Historique:
revised: 08 07 2021
received: 29 05 2021
accepted: 19 07 2021
pubmed: 23 7 2021
medline: 3 2 2022
entrez: 22 7 2021
Statut: ppublish

Résumé

Little is known aboutbiopsy findings and outcomes when kidney transplant recipients (KTRs) undergo biopsy for isolated proteinuria with stable serum creatinine (SCr). We analyzed all KTRs who underwent biopsy for isolated proteinuria with stable SCr between January 2016 and June 2020. Patients were divided into three groups based on the biopsy findings: Active Rejection (AR), Glomerulonephritis (GN), and Other. A total of 130 KTRs fulfilled our selection criteria; 38 (29%) in the AR group, 26 (20%) in the GN group, and 66 (51%) in the Other group. Most baseline characteristics were similar between the groups. In multivariate analysis, higher HLA mismatch (HR per mismatch: 1.30; 95% CI:1.06-1.59; P = .01) and male gender (HR: .45; 95% CI .23-.89; P = .02) were associated with AR. There was no significant correlation between the degree of proteinuria and rejection (r = .05, P = .58) or GN (r = .07, P = .53). Graft survival was also similar between the groups. Likely due to the early diagnosis without a significant rise in SCr, outcomes were similar among all three groups. Routine monitoring for proteinuria followed by a biopsy and appropriate management may help to identify early acute graft injury and prevent graft failure.

Identifiants

pubmed: 34291509
doi: 10.1111/ctr.14436
doi:

Substances chimiques

Creatinine AYI8EX34EU

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14436

Subventions

Organisme : Virginia Lee Cook Foundation

Informations de copyright

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

First MR, Vaidya PN, Maryniak RK, et al. Proteinuria following transplantation. Correlation with histopathology and outcome. Transplantation. 1984;38:607-612.
Fernández-Fresnedo G, Plaza JJ, Sánchez-Plumed J, Sanz-Guajardo A, Palomar-Fontanet R, Arias M. Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant. 2004;19(3):iii47-51.
López V, Sola E, Jironda C, et al. Biopsies in renal transplant patients with proteinuria: histological findings. Transplant Proc. 2011;43:2191-2193.
Reichel H, Zeier M, Ritz E. Proteinuria after renal transplantation: pathogenesis and management. Nephrol Dial Transplant. 2004;19:301-305.
Morath C, Zeier M. When should post-transplantation proteinuria be attributed to the renal allograft rather than to the native kidney?. Nat Clin Pract Nephrol. 2007;3:18-19.
Fernández-Fresnedo G, Escallada R, Rodrigo E, et al. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation. 2002;73:1345-1348.
Roodnat JI, Mulder PG, Rischen-Vos J, et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation. 2001;72:438-444.
Shamseddin MK, Knoll GA. Posttransplantation proteinuria: an approach to diagnosis and management. Clin J Am Soc Nephrol. 2011;6:1786-1793.
Amer H, Fidler ME, Myslak M, et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant. 2007;7:2748-2756.
Yakupoglu U, Baranowska-Daca E, Rosen D, Barrios R, Suki WN, Truong LD. Post-transplant nephrotic syndrome: a comprehensive clinicopathologic study. Kidney Int. 2004;65:2360-2370.
Parajuli S, Reville PK, Ellis TM, Djamali A, Mandelbrot DA. Utility of protocol kidney biopsies for de novo donor-specific antibodies. Am J Transplant. 2017;17:3210-3218.
Parajuli S, Astor BC, Kaufman D, et al. Which is more nephrotoxic for kidney transplants: BK nephropathy or rejection?. Clin Transplant. 2018;32:e13216.
Tsampalieros A, Knoll GA. Evaluation and management of proteinuria after kidney transplantation. Transplantation. 2015;99:2049-2060.
Akbari A, Fergusson D, Kokolo MB, et al. Spot urine protein measurements in kidney transplantation: a systematic review of diagnostic accuracy. Nephrol Dial Transplant. 2014;29:919-926.
Krishna KS, Pandey AP, Kirubakaran MG, Kanagasabapathy AS. Urinary protein/creatinine ratio as an indicator of allograft function following live related donor renal transplantation. Clin Chim Acta. 1987;163:51-61.
D'Cunha PT, Parasuraman R, Venkat KK. Rapid resolution of proteinuria of native kidney origin following live donor renal transplantation. Am J Transplant. 2005;5:351-355.
Sun Q, Jiang S, Li X, et al. The prevalence of immunologic injury in renal allograft recipients with de novo proteinuria. PLoS One. 2012;7:e36654.
Serón D, Burgos D, Alonso A. Histology and proteinuria after renal transplantation. Transplant Rev (Orlando). 2012;26:20-26.
Naesens M, Lerut E, Emonds MP, et al. Proteinuria as a noninvasive marker for renal allograft histology and failure: an observational cohort study. J Am Soc Nephrol. 2016;27:281-292.
Parajuli S, Joachim E, Alagusundaramoorthy S, et al. Subclinical antibody-mediated rejection after kidney transplantation: treatment outcomes. Transplantation. 2019;103:1722-1729.
Redfield RR, McCune KR, Rao A, et al. Djamali A: nature, timing, and severity of complications from ultrasound-guided percutaneous renal transplant biopsy. Transpl Int. 2016;29:167-172.
Parajuli S, Joachim E, Alagusundaramoorthy S, et al. Donor-specific antibodies in the absence of rejection are not a risk factor for allograft failure. Kidney Int Rep. 2019;4:1057-1065.
Kataria A, Kumar D, Gupta G. Donor-derived Cell-free DNA in solid organ transplant diagnostics: indications, limitations, and future directions. Transplantation. 2021.

Auteurs

Sandesh Parajuli (S)

Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Kurtis J Swanson (KJ)

Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

James Alstott (J)

Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Fahad Aziz (F)

Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Neetika Garg (N)

Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Weixiong Zhong (W)

Department of Pathology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Arjang Djamali (A)

Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Didier Mandelbrot (D)

Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH